Safety and Activity of SNX-5422 Plus Ibrutinib in CLL
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02914327|
Recruitment Status : Withdrawn (Lack of enrollment)
First Posted : September 26, 2016
Last Update Posted : July 30, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Drug: SNX-5422 plus ibrutinib||Phase 1|
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults and is not considered curable outside of allogeneic stem cell transplantation.
BTK is a critical kinase in the B cell receptor signaling pathway. This pathway is amplified in CLL and results in amplification of proliferation and anti-apoptotic signals. By inhibiting BTK, ibrutinib eliminates the activation of these pro-survival pathways and microenvironment survival signals. While response to ibrutinib has been high with therapy well-tolerated overall, some patients have relapsed while others have been taken off therapy for toxicity or other reasons. Relapse in CLL can be mediated by at least two separate mechanisms. One is by mutations in BTK, which both decrease ibrutinib's affinity for BTK, and also changes the binding from irreversible to reversible. This is a proof of concept study to investigate whether the addition of SNX-5422 to an established dose of ibrutinib will reduce mutated BTK from CLL cells and/or prevents or delays disease progression of subjects with CLL.
This is an open-label study of SNX‑5422 combined with ibrutinib. In each 28 day cycle, SNX‑5422 will be dosed in the morning once every other day for 21 days, followed by a 7‑day drug‑free period. Subjects will continue to receive daily oral ibrutinib at their established dose level in the afternoon every day for 28 days. cycle
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase 1, Open-label Study of SNX‑5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase|
|Actual Study Start Date :||February 2, 2017|
|Actual Primary Completion Date :||July 1, 2018|
|Actual Study Completion Date :||July 1, 2018|
Experimental: SNX-5422 plus ibrutinib
Open-label administration of SNX-5422 capsules dosed in the morning once every other day for 21 days (11 doses) followed by a 7 day drug free period and daily with the established ibrutinib dose for 28 days of a 28-days cycle. Subjects will repeat the 28-day schedule until the cancer progresses or the subject is unable to tolerate the therapy
Drug: SNX-5422 plus ibrutinib
SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Other Name: Imbruvica
- Efficacy of the combination of SNX-5422 and ibrutinib [ Time Frame: Every 12 weeks up to 52 weeks ]Change in percent of mutated BTK in CLL cells
- Number of subjects reporting adverse events [ Time Frame: Day 28 of each 4 week cycle from randomization up to 52 weeks ]Frequency and severity of adverse events
- Time to disease progression [ Time Frame: Up to 52 weeks ]Elapsed time for each subject from randomization to relapse of disease up to 52 weeks
- Clinical Laboratory testing [ Time Frame: Day 28 of each 4 week cycle from randomization up to 52 weeks ]Absolute values and changes from baseline for each subject using standard clinical chemistry, hematology and urinalysis parameters
- Electrocardiogram [ Time Frame: Pre-dose on Day 1 of each 4 week cycle from randomization up to 52 weeks ]Digital 12-lead ECG using standard recording methods at trough drug levels. All ECG recordings will be analyzed for PR, RR, QT intervals, and for morphology.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02914327
|United States, Ohio|
|Wexner Medical Center, Ohio State University|
|Columbus, Ohio, United States, 43210|